Furusawa Jun, Homma Akihiro, Onimaru Rikiya, Sakashita Tomohiro, Yoshida Daisuke, Hatakeyama Hiromitsu, Mizumachi Takatsugu, Kano Satoshi, Tsuchiya Kazuhiko, Yasuda Koichi, Shirato Hiroki, Fukuda Satoshi
Department of Otolaryngology-Head & Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan.
Department of Otolaryngology-Head & Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan.
Auris Nasus Larynx. 2015 Dec;42(6):443-8. doi: 10.1016/j.anl.2015.04.003. Epub 2015 Apr 28.
We retrospectively assessed the indications for superselective intra-arterial infusion of cisplatin with concomitant radiotherapy (RADPLAT) in patients with hypopharyngeal cancer (HPC).
Between April 2000 and March 2013, 41 previously untreated patients received superselective intra-arterial infusion of cisplatin (100-120mg/m(2) per week) with simultaneous intravenous infusions of thiosulfate to neutralize cisplatin toxicity and conventional radiotherapy (65-70Gy).
During the median follow-up period of 5.5 years, a statistically significant difference in the 5-year overall survival was noted between patients with N0-1 (n=14) and N2b-3 disease (n=27). One-half of deaths were observed to be the result of distant metastasis. The 5-year local control and overall survival were significantly better in patients with unilateral than in those with bilateral primary tumors. All the patients with T4b disease (n=3) died of disease within 2 years.
Indications for RADPLAT in patients with HPC were defined as patients with unilateral tumors staged as T3-4a and N0-1.
我们回顾性评估了下咽癌（HPC）患者超选择性动脉内输注顺铂联合放疗（RADPLAT）的适应证。
2000年4月至2013年3月期间，41例未经治疗的患者接受了超选择性动脉内输注顺铂（每周100 - 120mg/m²），同时静脉输注硫代硫酸盐以中和顺铂毒性，并接受常规放疗（65 - 70Gy）。
在中位随访期5.5年期间，N0 - 1期（n = 14）和N2b - 3期（n = 27）患者的5年总生存率存在统计学显著差异。观察到一半的死亡是远处转移所致。单侧原发性肿瘤患者的5年局部控制率和总生存率明显优于双侧原发性肿瘤患者。所有T4b期疾病患者（n = 3）在2年内均死于疾病。
HPC患者RADPLAT的适应证定义为单侧肿瘤分期为T3 - 4a且N0 - 1的患者。
